List of Excipients in Branded Drug PROPAFENONE HCL

« Back to Dashboard

Generic Drugs Containing PROPAFENONE HCL

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	propafenone hydrochloride	0591-0582	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	propafenone hydrochloride	0591-0582	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	propafenone hydrochloride	0591-0582	CROSPOVIDONE

What are the Most Frequently-Used Excipients in PROPAFENONE HCL?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	CROSPOVIDONE

Propafenone HCl Excipient Strategy and Commercial Opportunities

Last updated: October 7, 2026

Propafenone hydrochloride is a mature, genericized Class IC antiarrhythmic with limited brand exclusivity and meaningful formulation opportunity. The strongest commercial positions are in robust immediate-release tablets, modified-release capsules, dose-flexible strengths, lactose-free products, and manufacturing platforms that control content uniformity and dissolution across a narrow therapeutic window. Rythmol and Rythmol SR patents and regulatory exclusivities are no longer the primary barriers to entry; formulation quality, bioequivalence, supply reliability, and market access determine commercial success.

What is propafenone hydrochloride used for?

Propafenone HCl is a sodium-channel blocker used for rhythm control in selected patients with atrial fibrillation, atrial flutter, and life-threatening ventricular arrhythmias. In the United States, the immediate-release product is marketed in 150 mg, 225 mg, and 300 mg tablets. The extended-release product, Rythmol SR, is marketed in 225 mg, 325 mg, and 425 mg capsules [1,2].

Propafenone has clinically important pharmacokinetic variability because it is metabolized primarily through CYP2D6, with contributions from CYP3A4 and CYP1A2. Poor metabolizers and patients taking CYP2D6 inhibitors can have materially higher exposure. This makes formulation reproducibility and dissolution control commercially important, even though the drug is an established generic molecule.

Key product characteristics

Attribute	Propafenone HCl
Therapeutic class	Class IC antiarrhythmic
Primary dosage forms	Immediate-release tablets; extended-release capsules
U.S. brand	Rythmol; Rythmol SR
Immediate-release strengths	150 mg, 225 mg, 300 mg
Extended-release strengths	225 mg, 325 mg, 425 mg
Route	Oral
Dose frequency	Immediate release generally three times daily; extended release twice daily
Major metabolism	CYP2D6, CYP3A4, CYP1A2
Key formulation risks	Dose uniformity, dissolution, food effect, moisture sensitivity, polymorphism, tabletability
Generic status	Established ANDA market
Biologic or biosimilar exposure	Not applicable

What excipients are used in propafenone HCl products?

Public labeling identifies conventional excipient systems for propafenone immediate-release and extended-release products. Exact compositions vary by manufacturer and strength. Typical immediate-release tablet systems use lactose or another diluent, maize starch, povidone, a superdisintegrant, and magnesium stearate, with film-coating excipients such as hypromellose, polyethylene glycol, titanium dioxide, and talc [1,3].

Extended-release capsules generally use multiparticulate or matrix-based release technology. The commercial objective is to reduce peak-to-trough fluctuation and support twice-daily administration. Depending on the product, the drug may be incorporated into coated pellets, granules, or a polymer matrix inside a hard capsule [2,4].

Functional excipient map

Formulation function	Candidate excipients	Strategic purpose
Dilution	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Supports dose scaling and tablet mass
Binding	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports prompt drug release in immediate-release tablets
Lubrication	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and tooling performance
Flow improvement	Colloidal silicon dioxide	Improves powder flow and blend uniformity
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide	Protects tablets and improves swallowability
Sustained release	Ethylcellulose, hypromellose, methacrylate copolymers	Controls diffusion and release rate
Pelletization	Sugar spheres, microcrystalline cellulose, povidone	Provides multiparticulate cores
Moisture control	Low-moisture excipients, protective coatings, high-barrier packaging	Reduces hydrolysis and physical instability
Capsule shell	Gelatin or hypromellose	Supports conventional or vegetarian capsule positioning

Which excipient strategy is best for immediate-release propafenone tablets?

A conventional direct-compression or dry-granulation formulation is the most commercially practical route for immediate-release propafenone HCl. The preferred target is rapid, reproducible disintegration without excessive sensitivity to lubricant concentration, compression force, or storage humidity.

Recommended immediate-release platform

A robust starting platform would combine:

• Microcrystalline cellulose or a lactose-cellulose blend as the principal diluent.
• Crospovidone or croscarmellose sodium as the primary disintegrant.
• Povidone or copovidone as a dry binder if granulation is required.
• Colloidal silicon dioxide for flow control.
• Magnesium stearate at the lowest level that provides acceptable ejection.
• A thin hypromellose or polyvinyl alcohol film coat.

The main formulation objective is not maximum dissolution speed. It is consistent dissolution across all strengths and manufacturing lots. Propafenone doses are relatively high for a potent antiarrhythmic, so the formulation must maintain adequate tablet mass, blend uniformity, and mechanical strength.

Lactose versus lactose-free formulations

Lactose is commercially attractive because it is inexpensive, widely available, and compatible with conventional tablet manufacturing. A lactose-free formulation using microcrystalline cellulose, mannitol, or dibasic calcium phosphate can create a differentiated product for patients with lactose intolerance or for buyers seeking simplified excipient declarations.

The commercial value of lactose-free positioning is likely greater in hospital, institutional, and specialty-pharmacy channels than in the broad retail generic market. It does not, by itself, justify a premium unless paired with reliable supply, a differentiated package configuration, or a payer-access advantage.

Taste and swallowability

Propafenone HCl is an orally administered tablet drug, so taste masking is not normally a primary development issue. It can become relevant for:

• Orally disintegrating tablets.
• Pediatric or geriatric liquid products.
• Extemporaneous-compounding alternatives.
• Smaller, film-coated tablets that improve adherence.

A taste-masked liquid would require careful control of pH, preservative compatibility, solubility, and chemical stability. Because propafenone is a relatively high-dose drug, a liquid may require a concentrated suspension rather than a low-volume solution.

What excipient strategy is best for extended-release propafenone?

The strongest technical opportunity is an extended-release multiparticulate capsule that provides reproducible release independent of capsule fill variation and minimizes dose dumping.

Multiparticulate pellet approach

A pellet-based system can use drug-loaded inert or microcrystalline cellulose cores coated with functional polymers. Candidate release membranes include ethylcellulose for diffusion control and methacrylate copolymers for pH-dependent or pH-independent release behavior.

A multiparticulate product offers several advantages:

• Reduced sensitivity to local gastrointestinal conditions.
• Lower risk that one damaged unit releases the entire dose.
• Flexible capsule filling across 225 mg, 325 mg, and 425 mg strengths.
• Potential to blend pellet populations with different release rates.
• Better feasibility for capsule-size management than a single large matrix tablet.

The principal risks are process complexity, coating uniformity, pellet attrition, segregation, and the need to demonstrate comparable exposure to the reference extended-release product.

Matrix tablet approach

A hydrophilic matrix using hypromellose is simpler and less expensive than coated pellets. It may be suitable for a new extended-release product if the developer can establish:

• Release-rate consistency across strengths.
• Adequate mechanical strength.
• No dose dumping under alcohol challenge.
• Comparable food-effect behavior.
• Robust performance after storage under accelerated conditions.

A matrix system can be commercially attractive where manufacturing simplicity and low unit cost outweigh the flexibility of multiparticulate technology.

Food-effect control

Rythmol SR labeling instructs patients to take the product after a meal [2]. A new extended-release formulation that reduces food-effect variability could have meaningful clinical and commercial value, but the claim would require substantial pharmacokinetic evidence. The most realistic opportunity is not to eliminate food effect entirely, but to match the reference product reliably and provide clear administration instructions.

What manufacturing and excipient barriers affect propafenone products?

Propafenone HCl development has four major manufacturing barriers.

Blend uniformity and segregation

Different drug-loading levels across strengths can create segregation risk when particle size, density, or surface morphology differs between the active ingredient and excipients. This is particularly relevant for direct compression. Ordered mixing, particle-size control, and validated in-process sampling can reduce the risk.

Lubricant sensitivity

Excess magnesium stearate can reduce tablet tensile strength and slow dissolution. Under-lubrication can produce sticking, picking, and high ejection force. A sodium stearyl fumarate system may provide an alternative where magnesium stearate materially affects dissolution or compactability.

Moisture and chemical stability

A stability program should examine moisture uptake, assay, degradation products, dissolution, hardness, friability, and coating integrity. High-moisture excipients may be unsuitable if they accelerate degradation or alter release performance. High-barrier blister packaging can support a differentiated stability profile, especially for extended-release capsules.

Multiparticulate process control

For pellet products, coating weight gain and membrane uniformity are critical quality attributes. Small changes in coating thickness can change the release curve enough to affect bioequivalence. Process analytical technology, controlled spray conditions, and narrow particle-size distribution are likely to be more valuable than adding a large number of excipients.

What FDA regulatory status and Orange Book position does propafenone have?

Propafenone HCl is an established FDA-approved prescription drug with both immediate-release and extended-release reference products. FDA approved Rythmol tablets under NDA 019151 and Rythmol SR capsules under NDA 020849 [1,2].

The product is eligible for abbreviated new drug applications where the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference listed drug. Generic applicants must account for differences between immediate-release and extended-release products. An extended-release capsule cannot rely on the same development logic as an immediate-release tablet.

Orange Book status

The commercial Orange Book position is mature:

• Rythmol immediate-release tablets are the reference product for generic tablet development.
• Rythmol SR extended-release capsules are the reference product for extended-release capsule development.
• Original brand patent and regulatory exclusivity periods have expired.
• No current brand exclusivity is expected to block standard ANDA entry.
• Any active Orange Book patent listing should be verified against the current FDA Orange Book before filing or launch planning [5].

The primary regulatory risk is therefore bioequivalence and product quality, not loss of a remaining brand monopoly.

When does propafenone lose exclusivity?

Propafenone lost meaningful U.S. market exclusivity years ago. Rythmol was approved in 1989, and Rythmol SR was approved in 2003 [1,2]. Any original patent terms associated with those approvals have expired or become commercially immaterial.

The relevant entry pathways are:

• ANDA filing with Paragraph IV certification if an applicable listed patent remains.
• Paragraph III certification where a listed patent has not yet expired.
• Section viii method-of-use carve-outs where a patented use can be omitted.
• Standard ANDA approval where no blocking patent remains.

For a mature molecule such as propafenone, launch timing depends more on FDA review, manufacturing readiness, reference-product availability, and commercial contracting than on brand patent expiry.

Are there Paragraph IV challenges and propafenone patent litigation?

Propafenone has been subject to the ordinary generic competition associated with an old small-molecule product. The relevant litigation risk is concentrated in any remaining listed formulation or method-of-use patents, not in the active ingredient itself.

A Paragraph IV strategy would be commercially rational only if a current Orange Book patent creates a meaningful delay to approval or launch. Given the age of the Rythmol and Rythmol SR approvals, the likelihood of a material, long-duration patent barrier is low. A filing strategy should still review:

• Current Orange Book patent listings.
• Patent-term adjustments and pediatric extensions.
• FDA reference-listed-drug designations.
• Any litigation under the Hatch-Waxman framework.
• Settlement terms that could restrict an agreed launch date.

No biosimilar risk exists because propafenone is a chemically synthesized small molecule, not a biologic.

How strong is the patent estate for propafenone excipients and formulations?

The original active-ingredient estate is weak from an entry-barrier perspective. Commercially relevant patent opportunities are more likely to arise from new formulation architecture than from propafenone itself.

Potentially protectable formulation concepts

A developer could seek patent protection for:

• Specific multiparticulate pellet structures.
• Defined polymer coating ratios and release profiles.
• Alcohol-resistant extended-release formulations.
• Food-effect-reducing dosage forms.
• Low-moisture or moisture-protective compositions.
• Lactose-free formulations with specified dissolution performance.
• Smaller tablets or high-load tablets with improved manufacturability.
• Fixed-dose combinations, subject to clinical and regulatory requirements.
• Alternative dosage forms for patients unable to swallow tablets or capsules.

Patent strength will depend on measurable technical differences. Claims limited to routine substitution of one conventional filler for another are vulnerable to obviousness challenges. Stronger claims would link a defined excipient composition to a reproducible pharmacokinetic or dissolution result.

Geographic coverage

U.S. protection is largely relevant to FDA-listed patents and ANDA litigation. European protection would involve national validations, supplementary protection certificate history, and local patent status. In emerging markets, commercial barriers may be regulatory rather than patent-based. Supply-chain qualification and local registration can be more important than exclusivity.

What are the commercial opportunities for propafenone excipient innovation?

The market is unlikely to support a broad premium for a standard generic tablet. Opportunities are more credible where formulation design solves an identifiable clinical, manufacturing, or channel problem.

1. Reliable immediate-release generic

The lowest-risk opportunity is a standard 150 mg, 225 mg, and 300 mg tablet portfolio with:

• High batch-to-batch dissolution consistency.
• Multiple-count bottle and blister configurations.
• Competitive cost of goods.
• Strong shortage-prevention planning.
• Clean, compact excipient labeling.

This product competes on price, supply reliability, and pharmacy-channel availability.

2. Extended-release capsule alternative

A differentiated extended-release capsule can compete where manufacturers can demonstrate dependable bioequivalence and secure adequate supply of the reference product. Multiparticulate technology may support multiple strengths from a common platform, reducing development and manufacturing complexity.

3. Lactose-free or reduced-excipient product

A lactose-free product can target patients with excipient sensitivities and institutional buyers seeking simplified formularies. The opportunity is niche but practical. It is more defensible when combined with a tablet-size advantage, packaging differentiation, or a contract-manufacturing partnership.

4. Hospital and specialty distribution

Propafenone is used in cardiology and rhythm-management settings. Commercial opportunities include unit-dose packaging, calendar blister packs, and low-error labeling for dose titration. Packaging is particularly relevant because immediate-release dosing is frequent and regimen changes are common.

5. Global licensing and regional supply

Licensing opportunities may involve:

• A finished-dose manufacturer seeking an approved ANDA.
• A regional distributor seeking registration rights.
• A formulation company with extended-release technology.
• A contract development and manufacturing organization offering pellet or matrix production.

The most valuable asset is likely to be a fully developed, bioequivalent product with scalable manufacturing, rather than an early-stage excipient concept.

How does propafenone compare with competing antiarrhythmics?

Propafenone competes with flecainide for selected rhythm-control use and with amiodarone, sotalol, and dofetilide in broader antiarrhythmic treatment pathways. The excipient opportunity differs by product.

Drug	Formulation opportunity	Main commercial issue
Propafenone	IR tablets and ER capsules	Generic price pressure; bioequivalence
Flecainide	IR tablets and ER capsules	Similar adherence and release-control opportunity
Amiodarone	Tablets, injectable products	Complex safety profile and broad generic competition
Sotalol	Tablets and oral solution	Dose titration and renal dosing
Dofetilide	Capsules	Controlled initiation and limited prescriber base

Propafenone’s most direct formulation comparison is flecainide. Both have immediate- and modified-release market logic, but propafenone’s CYP2D6 metabolism and food-administration requirements make exposure control especially important.

What revenue exposure and generic launch scenarios exist?

Revenue exposure depends on product scope and channel strategy rather than exclusivity. A standard generic entrant faces rapid price compression once multiple suppliers are approved. A company with one approved immediate-release strength may have limited commercial leverage. A complete strength portfolio, extended-release capability, and reliable supply can improve contracting position.

Launch scenarios

Scenario	Product	Expected commercial profile
Basic entry	One or more IR strengths	Low development risk; high price competition
Portfolio entry	All IR strengths	Better pharmacy coverage and substitution potential
Modified-release entry	ER capsules	Higher development complexity; potentially less crowded
Differentiated entry	Lactose-free or low-moisture product	Niche premium potential
Platform entry	ER technology licensed to multiple partners	Royalty and manufacturing revenue
Specialty packaging	Unit-dose or adherence-focused packs	Institutional and specialty-channel opportunity

A company should avoid assuming that a formulation patent will create durable pricing power. FDA approval, supply continuity, and a complete strength portfolio are more likely to determine returns.

Key Takeaways

• Propafenone HCl is a mature small-molecule generic with no meaningful biologic or biosimilar issue.
• Rythmol and Rythmol SR exclusivity barriers are historical; current commercial entry is primarily an ANDA and bioequivalence exercise.
• Immediate-release products favor conventional excipient systems built around reliable disintegration, tablet strength, and dissolution.
• Extended-release products offer the strongest formulation opportunity through multiparticulate pellets, controlled-release matrices, and food-effect management.
• Lactose-free, low-moisture, unit-dose, and adherence-oriented products can create targeted differentiation.
• Patent value is more credible for defined release systems and measurable performance advantages than for routine filler substitution.
• Generic launch economics favor a full strength portfolio, strong supply reliability, and access to retail, institutional, and specialty channels.
• The most material technical risks are blend uniformity, lubricant sensitivity, moisture stability, release reproducibility, and extended-release bioequivalence.

FAQs

Is propafenone HCl suitable for a lactose-free tablet?

Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and suitable binders can replace lactose. The formulation must be reoptimized for flow, compaction, disintegration, and dissolution.

Can propafenone be developed as an orally disintegrating tablet?

Potentially, but the relatively high dose creates tablet-size and taste-masking constraints. An orally disintegrating product would need a clinically credible adherence or swallowing benefit to justify development cost.

What is the best polymer for propafenone extended release?

No single polymer is universally optimal. Hypromellose is practical for matrix tablets, while ethylcellulose and methacrylate copolymers are useful for coated multiparticulates. Selection depends on target release, food effect, alcohol resistance, and bioequivalence.

Does propafenone require a narrow therapeutic index formulation strategy?

Propafenone requires tight control of exposure and release because of pharmacokinetic variability and antiarrhythmic safety considerations. Developers should apply stringent dissolution and content-uniformity controls even where the FDA does not classify the product under a formal narrow-therapeutic-index framework.

Is a propafenone formulation patent likely to support premium pricing?

Only if the formulation produces a meaningful, defensible advantage such as improved food-effect performance, alcohol resistance, lower variability, reduced pill burden, or a clinically relevant administration benefit. Routine excipient substitution is unlikely to support durable premium pricing.

References

1. U.S. Food and Drug Administration. (1989). Rythmol (propafenone hydrochloride) tablets, prescribing information. NDA 019151.

2. U.S. Food and Drug Administration. (2003). Rythmol SR (propafenone hydrochloride) extended-release capsules, prescribing information. NDA 020849.

3. DailyMed. (n.d.). Propafenone hydrochloride tablets: prescribing information and inactive ingredients. U.S. National Library of Medicine.

4. DailyMed. (n.d.). Propafenone hydrochloride extended-release capsules: prescribing information. U.S. National Library of Medicine.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.